Prospective Observational Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma; Rhinosinusitis
- Focus Therapeutic Use
- 07 Nov 2019 Planned End Date changed from 1 Jan 2020 to 19 Oct 2018.
- 07 Nov 2019 Planned primary completion date changed from 1 Jan 2020 to 19 Oct 2018.
- 07 Nov 2019 Status changed from recruiting to withdrawn prior to enrolment.